174579-31-8

Basic information

• Product Name: TERT-BUTYL-4-AMINOPHENYLACETATE
• Synonyms: tert-Butyl 2-(4-aMinophenyl)acetate;2-(4-aMinophenyl)-3,3-diMethylbutanoate;4-Aminophenylacetic acid tert-butyl ester;4-AMino-benzeneacetic acid tert-butyl ester
• CAS NO: 174579-31-8
• Molecular Formula: C₁₂H₁₇NO₂
• Molecular Weight: 207.27
• Mol File: 174579-31-8.mol
• Article Data: 8

Chemical Properties

• Melting Point: 30-32°C
• Boiling Point: 310.6°Cat760mmHg
• Flash Point: 164.1°C
• Appearance: /
• Density: 1.067g/cm³
• Vapor Pressure: 0.000593mmHg at 25°C
• Refractive Index: 1.533
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: TERT-BUTYL-4-AMINOPHENYLACETATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL-4-AMINOPHENYLACETATE(174579-31-8)
• EPA Substance Registry System: TERT-BUTYL-4-AMINOPHENYLACETATE(174579-31-8)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 174579-31-8(Hazardous Substances Data)

Usage

General Description

"Tert-Butyl-4-aminophenylacetate" is a chemical compound with the molecular formula C12H17NO2. It is a white solid that is commonly used as a building block in organic synthesis and pharmaceutical manufacturing. tert-Butyl-4-aminophenylacetate is derived from 4-aminophenylacetic acid, which is a common starting material for the synthesis of various pharmaceuticals and organic compounds. Tert-Butyl-4-aminophenylacetate is known for its stability and relatively low reactivity, making it a valuable component in the production of various drugs and compounds. It is important to handle and store this chemical with care, as it can pose health and safety risks if not properly managed.

InChI:InChI=1/C12H17NO2/c1-12(2,3)15-11(14)8-9-4-6-10(13)7-5-9/h4-7H,8,13H2,1-3H3

Upstream product

• 29704-38-9 (4-nitrophenyl)acetic acid tert-butyl ester 
• 51656-70-3 (2-tert-butoxy-2-oxoethyl)zinc(II) bromide 
• 106-40-1 4-bromo-aniline 
• 104-03-0 4-nitrobenzeneacetic acid 

Downstream Products

• 174579-27-2 {4-[Bis-(2-hydroxy-ethyl)-amino]-phenyl}-acetic acid tert-butyl ester 
• 119054-10-3 {4-[Bis-(2-chloro-ethyl)-amino]-phenyl}-acetic acid tert-butyl ester 
• 10477-72-2 4-bis(2-chloroethyl)aminophenylacetic acid 
• 934464-17-2 C₅₂H₇₂N₄O₁₀ 
• 1034776-13-0 {4-[(1H-indole-6-carbonyl)-amino]-phenyl}-acetic acid tert-butyl ester 
• 1246636-77-0 tert-butyl 2-(4-((2,4-diaminopteridin-6-yl)methylamino)phenyl)acetate 
• 181519-06-2 tert-butyl 2-(4-isocyanatophenyl)acetate 
• 1314003-57-0 meptazinol 4-aminophenylacetic acid tert-butyl ester carbamate 
• 1314003-16-1 meptazinol para-aminophenylacetic acid carbamate hydrochloride 
• 90798-99-5 [4-(2-chloro-acetylamino)-phenyl]-acetic acid 
• 1469894-76-5 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl 7-(2-(4-(2-tert-butoxy-2-oxoethyl)phenylamino)-2-oxoethylamino)-7-oxoheptanoate 
• 1469894-61-8 2-(4-(2-(7-(2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yloxy)-7-oxoheptanamido)acetamido)phenyl)acetic acid 
• 1469894-68-5 tert-butyl 2-(4-(2-aminoacetamido)phenyl)acetate 
• 1469894-72-1 7-(benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-5-hydroxy-4-oxo-4H-chromen-3-yl 7-(2-(4-(2-tert-butoxy-2-oxoethyl)phenylamino)-2-oxoethylamino)-7-oxoheptanoate 

Relevant articles and documents

PYRIDAZINE-3-FORMAMIDE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF

Disclosed in the present invention are a pyridazine-3-formamide compound suitable for inhibiting or regulating the Janus kinase (JAK), in particular tyrosine kinase 2 (TYK2), and a preparation method therefor and the medical use thereof. In particular, disclosed in the present invention are a compound as represented by general formula (I) and a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the compound or the pharmaceutically acceptable salt thereof, a method for treating and/or preventing Janus kinase-mediated related diseases, in particular autoimmune diseases, inflammatory diseases and cancers, by means of using the compound or the pharmaceutically acceptable salt thereof, and a method for preparing the compound or the pharmaceutically acceptable salt thereof. Each substituent of general formula (I) has the same definition as that in the description.

Macrocyclic BACE1 inhibitors with hydrophobic cross-linked structures: Optimization of ring size and ring structure

Based on the X-ray crystallography of recombinant BACE1 and a hydroxyethylamine-type peptidic inhibitor, we introduced a cross-linked structure between the P1 and P3 side chains of the inhibitor to enhance its inhibitory activity. The P1 and P3 fragments bearing terminal alkenes were synthesized, and a ring-closing metathesis of these alkenes was used to construct the cross-linked structure. Evaluation of ring size using P1 and P3 fragments with various side chain lengths revealed that 13-membered rings were optimal, although their activity was reduced compared to that of the parent compound. Furthermore, the optimal ring structure was found to be a macrocycle with a dimethyl branched substituent at the P3 β-position, which was approximately 100-fold more active than the non-substituted macrocycle. In addition, the introduction of a 4-carboxymethylphenyl group at the P1′ position further improved the activity.

Palladium-catalyzed α-arylation of zinc enolates of esters: Reaction conditions and substrate scope

The intermolecular α-arylation of esters by palladium-catalyzed coupling of aryl bromides with zinc enolates of esters is reported. Reactions of three different types of zinc enolates have been developed. α-Arylation of esters occurs in high yields with i